Yongfen Xu

Dr. Yongfen Xu

CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Current Opinion in Immunology
Verified
Journal Article
Closed access
Yongfen XuYongfen Xu
Yongfen Xu
JZJin Zhong
Jin Zhong


28 March 2022 in The EMBO Journal
Verified
Journal Article
Closed access
YZYuqiang Zhang
Yuqiang Zhang
YDYunpeng Dai
Yunpeng Dai
JWJiaxin Wang
Jiaxin Wang
YXYan Xu
Yan Xu
ZLZhe Li
Zhe Li
YLYang Li
Yang Li

1 July 2020 in Antiviral Research
Verified
Journal Article
Closed access
YQYue Qi
Yue Qi
LHLin Han
Lin Han
YQYanfei Qi
Yanfei Qi
XJXia Jin
Xia Jin
BZBo Zhang
Bo Zhang
Yongfen XuYongfen Xu
Yongfen Xu

25 September 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MTMarion TARBE
Marion TARBE
WDWei Dong
Wei Dong
GHGuang Hu
Guang Hu
Yongfen XuYongfen Xu
Yongfen Xu
JSJing Sun
Jing Sun
QLQibin Leng
Qibin Leng
Japanese encephalitis virus (JEV) exposure or vaccination could elicit cross-reactive CD8 T cell immunity against heterologous flaviviruses in humans. In addition, cross-reactive CD8 T cells induced by dengue virus (DENV) have been shown to play a protective role against Zika virus (ZIKV). However, how JEV exposure or vaccination affects ZIKV infection in humans remains unclear. In this report, epitope prediction algorithms were used to predict the cross-reactive CD8 T cell epitope restricted to human HLA between JEV and ZIKV. We found that these predicted CD8 T cell epitopes are immunogenic and cross-reactive in humanized HLA transgenic mice. Moreover, JEV vaccine immunization provided cross-protection against ZIKV infection. Furthermore, CD8 T cells were involved in the protection against ZKIV infection in vivo. Our results have an important clinical implication that vaccination with JEV SA14-14-2 may provide protection against ZIKV infection in humans.

18 May 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
MGMingzhe Guo
Mingzhe Guo
LYLiqing Ye
Liqing Ye
TYTao Yu
Tao Yu
LHLin Han
Lin Han
QLQingchao Li
Qingchao Li
Yongfen XuYongfen Xu
Yongfen Xu